Streetwise Biotech/Pharmaceuticals Articles

Biotech's Target Price Increased as Shares 'Deeply Undervalued'
Source: Streetwise Reports  (11/15/17)
Wedbush analyst Robert Driscoll provided an update on the lead asset of this drug developer targeting cancer.
More >

John McCamant

Biotech Targets 'Blockbuster' Markets; Less-Addictive Opioid Painkiller Set for FDA Filing
Source: John McCamant for Streetwise Reports  (11/15/17)
Medical Technology Stock Letter editor John McCamant outlines the reasons behind the buy rating and target price increases for a company that, in addition to developing an alternative to addictive opioids for pain relief, has candidates targeting multiple immune disorders and cancer.
More >

Analyst Says Biotech Share Price Could Potentially 'Double'
Source: Streetwise Reports  (11/13/17)
Analyst Grant Zeng of Zacks Small Cap Research examines what transpired with this biopharmaceutical company during Q3/17. More >

Biotech with Solid Pipeline and 'Solid Partnership Outlook'
Source: Streetwise Reports  (11/13/17)
Analyst Kevin DeGeeter, with Ladenburg Thalmann, relayed the highlights from his recent meeting with this company's management team about near-term clinical news and pipeline plans.
More >

Biotech Reports Positive Topline Data; Biologics License Application in Progress
Source: Streetwise Reports  (11/6/17)
Ram Selvaraju, an analyst with H.C. Wainwright & Co., reviewed the recent clinical trial results released by this developer of cell therapies targeting oncology and orphan indications.
More >

Target Price Raised on 'Undervalued' Antibiotics Developer
Source: Streetwise Reports  (11/6/17)
Analyst Ed Arce discussed the rationale behind H.C. Wainwright & Co.'s decision to revise its models on this clinical-stage biopharmaceutical company. More >

John McCamant

Drug Offers 'Best-in-Class' Potential
Source: John McCamant for Streetwise Reports  (11/1/17)
John McCamant, editor of the Medical Technology Stock Letter, initiated coverage on a company that he calls an emerging leader in women's health. More >

Big Biotech's Value Is Bolstered by Focus on Alzheimer's Disease
Source: Streetwise Reports  (11/1/17)
An analysis of this company's quarterly update highlights a pipeline studded with candidates targeting neurological indications. More >

Biopharmaceutical Firm Receives FDA Priority Review and PDUFA Date
Source: Streetwise Reports  (10/25/17)
Neil Maruoka, an analyst with Canaccord Genuity, provided an update on this biotech's progress through the regulatory approval process for one of its therapeutics. More >

Analyst Calls Biotech with Alzheimer's Therapy a 'High Risk, High Reward Opportunity'
Source: Streetwise Reports  (10/25/17)
Mackie Research reported on this company's recent announcement about one of its product candidates targeting Alzheimer's disease. More >

Coverage Initiated on Gene Therapy Company
Source: Streetwise Reports  (10/25/17)
Analyst David Nierengarten with Wedbush explained the rationale for adding this biotech to his coverage universe.
More >

Biotech Announces 'Late-Breaking' Addition to Immunotherapy Conference
Source: Streetwise Reports  (10/18/17)
Michael King Jr., an analyst with JMP Securities, reported this biopharmaceutical firm was recently added to the roster of presenters scheduled for an upcoming annual meeting. More >

Biotech Releases Initial Zika Vaccine Trial Results; Advances Combo Trials
Source: Streetwise Reports  (10/18/17)
With multiple candidates in the pipeline advancing through clinical trials, Ram Selvaraju, an analyst with H.C. Wainwright & Co., provided insight into developments at a biotech addressing Zika virus, advanced bladder cancer and cervical dysplasia.
More >

Ron Struthers

Gold at Year-End and a Lesson in Shorting
Source: Ron Struthers for Streetwise Reports  (10/17/17)
Ron Struthers of Struthers' Resource Stock Report provides his outlook on gold stock performance going into the end of the year, offers a lesson in Shorting 101, and discusses his views on particular companies.
More >

Cannabis Company Forms Partnership to Develop Pharmaceuticals
Source: Streetwise Reports  (10/6/17)
Analyst Russell Stanley with Echelon Wealth Partners explained the significance of the recent licensing agreement signed by this Canadian medical marijuana producer and distributor. More >

Colin Lee Novick

Japan Is Fertile Ground for Biotech Deals
Source: Streetwise Reports  (10/4/17)
Japan and the United States are hotspots for companies that are looking to license-out exciting regenerative medicine technology, says Colin Lee Novick, managing director of CJ PARTNERS. In this interview with The Life Sciences Report, Novick discusses a regenerative medicine company pursuing partnerships in Japan for its cell therapies to treat chronic tendinosis, damaged or aged skin, and pattern baldness. More >

Small Biotech Enters Patent Deal with British Company Targeting Schizophrenia
Source: Streetwise Reports  (10/4/17)
A small-cap American biotech has secured a patent agreement with a larger British firm, garnering the attention of three sector analysts.
More >

Biotech with Transformative RNAi Delivery System Set for Multiple Catalysts by Year-End
Source: Streetwise Reports  (10/4/17)
With data from multiple studies due out this quarter, this biotech's RNA interference delivery platform has the potential to transform treatments for indications from cancer to ophthalmology, says Dr. Geert Cauwenbergh, President and CEO of RXi Pharmaceuticals, Dr. Gerrit Dispersyn, RXi's Chief Development Officer, and Dr. Karen Bulock, Vice President of Research at RXi.
More >

Immunotherapy Firm's Technology Demonstrates 'Potential Use in Treating Cancers and Bacterial Infections'
Source: Streetwise Reports  (9/27/17)
H.C. Wainwright & Co. reported the results of animal studies conducted using therapeutics created by this cancer and chronic infectious disease vaccine developer. More >

Possible 'Best-in-Class' Alzheimer's Drug Candidate Offers 'Disruptive' Potential
Source: Streetwise Reports  (9/20/17)
André Uddin, an analyst with Mackie Research, explained the rationale for adding this neurodegenerative disease biotech company to his firm's coverage universe. More >

Gout, Kidney Stones, Liver Disease & Cannabinoids
Source: Danny Deadlock for Streetwise Reports  (9/15/17)
Danny Deadlock, founder of, profiles a company that is working on a novel drug delivery technology with a focus on cannabinoids for the potential to treat various major diseases. More >

Biopharma Gets Green Light for Hypertension Study
Source: Streetwise Reports  (9/13/17)
Jason McCarthy, an analyst at Maxim Group, discussed this France-based biotech firm's near-term clinical trial and catalysts. More >

Small-Cap Biotech Benefits from First FDA Approval of CAR-T Therapy
Source: Streetwise Reports  (9/1/17)
The first approval of a cell therapy for treatment of pediatric blood cancer prompted H. C. Wainwright to increase its price target for a UK-based biotech manufacturing one of the therapy's components.
More >

With Acquisition of Kite Pharma, Gilead Becomes a 'Major Player' in CAR-T Arena
Source: Streetwise Reports  (8/30/17)
Jason Kolbert, analyst with Maxim Group, assesses the billion-dollar transaction that would bring Kite Pharma and the earning potential of its cell therapy programs under the larger biotech's umbrella.
More >

Analyst Says Cell Therapy Company's Move Decreases Risk
Source: Streetwise Reports  (8/23/17)
A regenerative medicine company has signed on to the ThawSTAR Early Adopter Program, a move analyst Douglas Loe of Echelon Wealth Partners terms "positive logistically" to development risk. More >

Showing Results: 1 to 25 of 678 Next

Get Our Streetwise Reports Newsletter Free

A valid email address is required to subscribe